Study on the Correlation Between theⅣPlase of Diabetic Nephropathy and Bailing Capsules Combied with Salvianolate
- VernacularTitle:百令胶囊联合丹参多酚酸盐对糖尿病肾病Ⅳ期的相关性研究
- Author:
Ping WANG
;
Shiwen WAN
;
Xinzhi DU
;
Yanmei XUE
;
Huizhi GAO
;
Yan YAN
;
Yanpin WU
- Publication Type:Journal Article
- Keywords:
Diabetic nephropathy in Ⅳ phase;
Endothelial dysfunction;
Inflammation;
Bailing capsules;
Salvianolate
- From:
China Pharmacist
2016;19(3):524-526
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the effects of Bailing capsules combined with salvianolate on inflammatory cytokines, renal vas-cular endothelia and renal function in diabetic nephropathy inⅣphase. Methods:Totally 60 patients with diabetic nephropathy in IV phase were randomly divided into the control group (30 cases) and the treatment group (30 cases). The control group was given the conventional and salvianolate therapy, and the treatment group was treated with Bailing capsules additionally. The treatment course was 3 months. The changes of serum creatine(SCr), urean itrogen (BUN), creatinine clearance rate (Ccr), ethelin (ET-1), interleukin-6 (IL-6), tumor necrosis factor (TNF-a) and C-reactive protein (CRP) were detected before and after the treatment. Results:After the 3-month treatment, SCr, BUN, IL-6, TNF-a, CRP and ET-1 were significantly decreased in the two groups with statistical signifi-cance, and Ccr was significantly increased in the treatment group (P<0. 05), and the changes in the treatment group were significant-ly better than those in the control group (P<0. 05). After the treatment, the blood glucose, blood lipids, glycosylated hemoglobin and the other indicators had no significant changes in the two groups (P>0. 05). There was no significant difference in the incidence of adverse drug reactions between the two groups (P>0. 05). Conclusion:The combination of Bailing capsules and salvianolate can re-duce the inflammatory reaction and improve renal vascular endothelial function and renal function in the patients with diabetic nephrop-athy in Ⅳ phase with promising safety and few adverse reactions.
